Press Releases Takeda Pharmaceutical Company Limited

Stocks

4502

JP3463000004

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 02:30:00 2026-07-17 EDT			5-day change	1st Jan Change
5,480.00 ^JPY	+2.53%		+2.26%	+13.34%

07-17	Asian Equities Traded in the US as American Depositary Receipts Fall in Friday Trading	MT
07-17	Takeda Pharmaceutical Reports Positive Phase 3 Data for Zasocitinib in Moderate-to-Severe Plaque Psoriasis	MT

Press Releases

07-16	Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies	BU
07-15	Takeda Pharmaceutical : to Hold Earnings Call for Fiscal Year 2026 1st Quarter on July 30	PU
07-12	Takeda and the Indonesian Government Announce Landmark Collaboration to Strengthen Healthcare Resilience and Expand Access to Lifesaving Plasma-Derived Medicinal Products	BU
07-09	Takeda Pharmaceutical : Filing of Corporate Governance Report to the Tokyo Stock Exchange	PU
07-08	Takeda Pharmaceutical : Completed Issuance of New Shares and Disposal of Treasury Shares under the Long-Term Incentive Plan for Company Group Employees Outside of Japan with Partial Forfeiture of Rights Granted to Allottees	PU
06-24	Takeda Pharmaceutical : Integrated Report (AIR 2026 EN)	PU
06-24	Takeda Announces New Assignments of Directors and Appointment of Julie Kim as Representative Director, President and CEO	BU
06-15	New Pivotal Study Data Show Takeda’s Oveporexton Improved Daily Function, Cognition and Nighttime Sleep for People with Narcolepsy Type 1	BU
06-11	Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations	BU
06-09	U.S. FDA Accepts Takeda's Application for Intravenous ENTYVIO® (vedolizumab) in Pediatric Ulcerative Colitis and Crohn's Disease	BU
06-09	Takeda Pharmaceutical : Notice Concerning Issuance of New Shares and Disposal of Treasury Shares under the Long-Term Incentive Plan for Company Group Employees Outside of Japan	PU
06-05	Takeda Pharmaceutical : Updates FY2025 Financial Results Based on Impact of AMITIZA® Antitrust Verdict	PU
06-01	Takeda Pharmaceutical : Notice Concerning Withdrawal of Shelf Registration Statement and Filing of New Shelf Registration Statement in Japan	PU
05-19	Takeda Pharmaceutical Company Limited: Takeda Provides an Update regarding Jury Verdict in AMITIZA® (lubiprostone) Antitrust Litigation in the U.S. and Related Revision to FY2025 Financial Results	EQ
05-18	Takeda Pharmaceutical : Provides an Update regarding Jury Verdict in AMITIZA® (lubiprostone) Antitrust Litigation in the U.S. and Related Revision to FY2025 Financial Results	PU
05-18	Attorneys at Hagens Berman Announce $474M Win in Amitiza Jury Trial Against Takeda	BU
05-16	Pharmaceutical company Takeda announces sweeping cutbacks; impact on Belgian division unclear	AQ
05-13	Takeda Pharmaceutical : Continuation of the Stock Compensation Plan for Directors and the Stock Grant System for Company Management in Japan in 2026	PU
05-13	Takeda Pharmaceutical : Earnings Report（Kessan Tanshin）Earnings Report（Kessan Tanshin）Download Earnings Report（Kessan Tanshin） (qr2025 q4 er en)	PU
05-13	Takeda Pharmaceutical : PresentationPresentationDownload Presentation (qr2025 q4 p01 en)	PU
05-13	Takeda Pharmaceutical : Quarterly Financial ReportQuarterly Financial ReportDownload Quarterly Financial Report (qr2025 q4 qfr en)	PU
05-13	Takeda Pharmaceutical : Quarterly Highlights InfographicQuarterly Highlights InfographicDownload Quarterly Highlights Infographic (FY25Q4 EN Takeda Infographic)	PU
05-13	Takeda Pharmaceutical : Clinical Trials Summary (Clinical Trial Summary May 2026)	PU
05-13	Takeda Announces FY2025 Full Year Results and FY2026 Outlook, Highlighted by Excellent Pipeline Progress and Solid FY2025 Results	BU
05-13	Takeda Pharmaceutical : Announces FY2025 Full Year Results and FY2026 Outlook, Highlighted by Excellent Pipeline Progress and Solid FY2025 Results	PU